The protective role of postoperative radiation therapy in low and intermediate grade major salivary gland malignancies: A study of the Canadian Head and Neck Collaborative Research Initiative.
acinar cell
adjuvant
carcinoma
mucoepidermoid
parotid neoplasms
radiation therapy
salivary gland neoplasms
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 10 2023
15 10 2023
Historique:
revised:
11
05
2023
received:
31
01
2023
accepted:
18
05
2023
medline:
22
9
2023
pubmed:
4
7
2023
entrez:
4
7
2023
Statut:
ppublish
Résumé
The objective of this study was to examine the utility of postoperative radiation for low and intermediate grade cancers of the parotid and submandibular glands. The authors conducted a retrospective, Canadian-led, international, multi-institutional analysis of a patient cohort with low or intermediate grade salivary gland cancer of the parotid or submandibular gland who were treated from 2010 until 2020 with or without postoperative radiation therapy. A multivariable, marginal Cox proportional hazards regression analysis was performed to quantify the association between locoregional recurrence (LRR) and receipt of postoperative radiation therapy while accounting for patient-level factors and the clustering of patients by institution. In total, 621 patients across 14 tertiary care centers were included in the study; of these, 309 patients (49.8%) received postoperative radiation therapy. Tumor histologies included 182 (29.3%) acinic cell carcinomas, 312 (50.2%) mucoepidermoid carcinomas, and 137 (20.5%) other low or intermediate grade primary salivary gland carcinomas. Kaplan-Meier LRR-free survival at 10 years was 89.0% (95% confidence interval [CI], 84.9%-93.3%). In multivariable Cox regression analysis, postoperative radiation therapy was independently associated with a lower hazard of LRR (adjusted hazard ratio, 0.53; 95% CI, 0.29-0.97). The multivariable model estimated that the marginal probability of LRR within 10 years was 15.4% without radiation and 8.8% with radiation. The number needed to treat was 16 patients (95% CI, 14-18 patients). Radiation therapy had no benefit in patients who had early stage, low-grade salivary gland cancer without evidence of nodal disease and negative margins. Postoperative radiation therapy may reduce LLR in some low and intermediate grade salivary gland cancers with adverse features, but it had no benefit in patients who had early stage, low-grade salivary gland cancer with negative margins.
Sections du résumé
BACKGROUND
The objective of this study was to examine the utility of postoperative radiation for low and intermediate grade cancers of the parotid and submandibular glands.
METHODS
The authors conducted a retrospective, Canadian-led, international, multi-institutional analysis of a patient cohort with low or intermediate grade salivary gland cancer of the parotid or submandibular gland who were treated from 2010 until 2020 with or without postoperative radiation therapy. A multivariable, marginal Cox proportional hazards regression analysis was performed to quantify the association between locoregional recurrence (LRR) and receipt of postoperative radiation therapy while accounting for patient-level factors and the clustering of patients by institution.
RESULTS
In total, 621 patients across 14 tertiary care centers were included in the study; of these, 309 patients (49.8%) received postoperative radiation therapy. Tumor histologies included 182 (29.3%) acinic cell carcinomas, 312 (50.2%) mucoepidermoid carcinomas, and 137 (20.5%) other low or intermediate grade primary salivary gland carcinomas. Kaplan-Meier LRR-free survival at 10 years was 89.0% (95% confidence interval [CI], 84.9%-93.3%). In multivariable Cox regression analysis, postoperative radiation therapy was independently associated with a lower hazard of LRR (adjusted hazard ratio, 0.53; 95% CI, 0.29-0.97). The multivariable model estimated that the marginal probability of LRR within 10 years was 15.4% without radiation and 8.8% with radiation. The number needed to treat was 16 patients (95% CI, 14-18 patients). Radiation therapy had no benefit in patients who had early stage, low-grade salivary gland cancer without evidence of nodal disease and negative margins.
CONCLUSIONS
Postoperative radiation therapy may reduce LLR in some low and intermediate grade salivary gland cancers with adverse features, but it had no benefit in patients who had early stage, low-grade salivary gland cancer with negative margins.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3263-3274Informations de copyright
© 2023 American Cancer Society.
Références
Hadiprodjo D, Ryan T, Truong MT, Mercier G, Subramaniam RM. Parotid gland tumors: preliminary data for the value of FDG PET/CT diagnostic parameters. AJR Am J Roentgenol. 2012;198(2):W185-W190. doi:10.2214/AJR.11.7172
Everson JWAP, Gnepp DR, El-Naggar AK. Tumours of the salivary glands. In: Barnes L, Eveson JW, Reichart P, Sidransky D, eds. Pathology and Genetics: Head and Neck Tumours. WHO Classification of Tumors. 3rd ed. Vol. 9. IARC Press; 2005:212-215.
Seethala RR, Stenman G. Update from the 4th edition of the World Health Organization Classification of Head and Neck Tumours: Tumors of the Salivary Gland. Head Neck Pathol. 2017;11(1):55-67. doi:10.1007/s12105-017-0795-0
Morand GB, Alsayegh R, Mlynarek AM, et al. Application of the Milan system for reporting salivary gland cytopathology using cell blocks. Virchows Arch. 2022;481(4):575-583. doi:10.1007/s00428-022-03364-x
Bell RB, Dierks EJ, Homer L, Potter BE. Management and outcome of patients with malignant salivary gland tumors. J Oral Maxillofac Surg. 2005;63(7):917-928. doi:10.1016/j.joms.2005.03.006
Pusztaszeri M, Baloch Z, Vielh P, Faquin WC. Application of the Milan system for reporting risk stratification in salivary gland cytopathology. Cancer Cytopathol. 2018;126(1):69-70.
Freiberger SN, Brada M, Fritz C, et al. SalvGlandDx-a comprehensive salivary gland neoplasm specific next generation sequencing panel to facilitate diagnosis and identify therapeutic targets. Neoplasia. 2021;23(5):473-487. doi:10.1016/j.neo.2021.03.008
Rupp NJ, Holler S, Brada M, et al. Expanding the clinicopathological spectrum of TGFBR3-PLAG1 rearranged salivary gland neoplasms with myoepithelial differentiation including evidence of high-grade transformation. Genes Chromosomes Cancer. 2022;61(2):94-104. doi:10.1002/gcc.23009
Hocwald E, Korkmaz H, Yoo GH, et al. Prognostic factors in major salivary gland cancer. Laryngoscope. 2001;111(8):1434-1439.
Grasl S, Janik S, Faisal M, et al. Influence of grading on management and outcome in mucoepidermoid carcinoma of the parotid-a multi-institutional analysis. Laryngoscope. 2023;133(1):124-132.
Erovic BM, Shah MD, Bruch G, et al. Outcome analysis of 215 patients with parotid gland tumors: a retrospective cohort analysis. J Otolaryngol Head Neck Surg. 2015;44:43.
Karimian S, Hullner MW, Rupp NJ, Freiberger SN, Broglie MA, Morand GB. Potential role of hybrid PET (PET/CT and PET/MR) in preoperative assessment of primary salivary gland carcinomas. J Laryngol Otol. 2023;137(5):551-555. doi:10.1017/S0022215122001475
Armstrong JG, Harrison LB, Spiro RH, Fass DE, Strong EW, Fuks ZY. Malignant tumors of major salivary gland origin: a matched-pair analysis of the role of combined surgery and postoperative radiotherapy. Arch Otolaryngol Head Neck Surg. 1990;116(3):290-293.
Scherl C, Kato MG, Erkul E, et al. Outcomes and prognostic factors for parotid acinic cell carcinoma: a National Cancer Database study of 2362 cases. Oral Oncol. 2018;82:53-60.
Bakst RL, Su W, Ozbek U, et al. Adjuvant radiation for salivary gland malignancies is associated with improved survival: a National Cancer Database analysis. Adv Radiat Oncol. 2017;2(2):159-166.
Cheraghlou S, Kuo P, Mehra S, et al. Adjuvant therapy in major salivary gland cancers: analysis of 8580 patients in the National Cancer Database. Head Neck. 2018;40(7):1343-1355.
Safdieh J, Givi B, Osborn V, Lederman A, Schwartz D, Schreiber D. Impact of adjuvant radiotherapy for malignant salivary gland tumors. Otolaryngol Head Neck Surg. 2017;157(6):988-994.
Cho JK, Lim BW, Kim EH, et al. Low-grade salivary gland cancers: treatment outcomes, extent of surgery and indications for postoperative adjuvant radiation therapy. Ann Surg Oncol. 2016;23(13):4368-4375. doi:10.1245/s10434-016-5353-6
Zenga J, Parikh AS, Emerick KS, Lin DT, Faquin WC, Deschler DG. Close margins and adjuvant radiotherapy in acinic cell carcinoma of the parotid gland. JAMA Otolaryngol Head Neck Surg. 2018;144(11):1011-1016. doi:10.1001/jamaoto.2018.0788
Gomez DR, Katabi N, Zhung J, et al. Clinical and pathologic prognostic features in acinic cell carcinoma of the parotid gland. Cancer. 2009;115(10):2128-2137. doi:10.1002/cncr.24259
Geiger JL, Ismaila N, Beadle B, et al. Management of salivary gland malignancy: ASCO guideline. J Clin Oncol. 2021;39(17):1909-1941.
Eby LS, Johnson DS, Baker HW. Adenoid cystic carcinoma of the head and neck. Cancer. 1972;29(5):1160-1168.
Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat Simulat Comput. 2009;38(6):1228-1234.
Lee EW, Wei LJ, Amato DA, Leurgans S. Cox-type regression analysis for large numbers of small groups of correlated failure time observations. In: Klein JP, Goel PK, eds. Survival Analysis: State of the Art. Springer Netherlands; 1992:237-247.
El-Naggar AK, Chan JK, Grandis JR, Takata T, Slootweg PJ, eds. WHO Classification of Head and Neck Tumours. World Health Organization Classification of Tumors. 4th ed. Vol. 9. IARC Press; 2017.
Chen AM, Lau VH, Farwell DG, Luu Q, Donald PJ. Mucoepidermoid carcinoma of the parotid gland treated by surgery and postoperative radiation therapy: clinicopathologic correlates of outcome. Laryngoscope. 2013;123(12):3049-3055.
Boon E, Valstar MH, van der Graaf WTA, et al. Clinicopathological characteristics and outcome of 31 patients with ETV6-NTRK3 fusion gene confirmed (mammary analogue) secretory carcinoma of salivary glands. Oral Oncol. 2018/07/01/2018;82:29-33. doi:10.1016/j.oraloncology.2018.04.022
National Lung Screening Research Team; Aberle DF, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365(5):395-409. doi:10.1056/NEJMoa1102873
Hair JF Jr, Black WC, Babin BJ Anderson RE. Multivariate Data Analysis. 7th ed. Pearson; 2009.
VanderWeele T. On a square-root transformation of the odds ratio for a common outcome. Epidemiology. 2017;28(6):e58-e60.
Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in Cox regression. Stat Med. 1995;14(15):1707-1723. doi:10.1002/sim.4780141510
Hong WJ, Chang SL, Tsai CJ, et al. The effect of adjuvant radiotherapy on clinical outcomes in early major salivary gland cancer. Head Neck. 2022;44(12):2865-2874. doi:10.1002/hed.27203
Andreoli MT, Andreoli SM, Shrime MG, Devaiah AK. Radiotherapy in parotid acinic cell carcinoma: does it have an impact on survival? Arch Otolaryngol Head Neck Surg. 2012;138(5):463-466.
Chen AM, Garcia J, Granchi PJ, Johnson J, Eisele DW. Late recurrence from salivary gland cancer: when does “cure” mean cure? Cancer. 2008;112(2):340-344.
Bhattacharyya N, Richardson ME, Gugino LD. An objective assessment of the advantages of retrograde parotidectomy. Otolaryngol Head Neck Surg. 2004;131(4):392-396.
Stankovic P, Wittlinger J, Timmesfeld N, et al. Antero- vs. retrograde nerve dissection in parotidectomy: a systematic review and meta-analysis. Eur Arch Otorhinolaryngol. 2018;275(6):1623-1630.
Westreich D, Greenland S. The table 2 fallacy: presenting and interpreting confounder and modifier coefficients. Am J Epidemiol. 2013;177(4):292-298.